Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Fennec Pharmaceuticals Granted FDA Approval For PEDMARK

FDA
News

Fennec Pharmaceuticals Granted FDA Approval For PEDMARK

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212937

byBenzinga Newsdesk

September 20, 2022

1 minute read

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212937

Morgan Stanley Maintains Overweight on Allegiant Travel, Lowers Price Target to $200

By Benzinga Newsdesk

August 24, 7:49 AM

Morgan Stanley analyst Ravi Shanker maintains Allegiant Travel (NASDAQ:ALGT) with a Overweight and lowers the price target from $237 to $200.

ALGT

Couchbase Sees Q3 Revenue $42.7M-$43.3M Vs $43.63M Est.; FY24 Revenue $171.7M-$174.7M Vs $173.39M Est.

By Happy Mohamed

September 6, 4:15 PM

Financial Outlook For the third quarter and full year of fiscal 2024, Couchbase

BASE

Cognex Clocks 29% Revenue Decline In Q1, Mirroring Broader Macroeconomic Softness

By Nabaparna Bhattacharya

May 4, 3:48 PM

Cognex Corporation (NASDAQ:CGNX) reported a first-quarter FY23 revenue decline of 28.8% to $201.12 million, beating the consensus of $192.01 million.…

CGNX

Why This Instacart Analyst Is Sidelined After IPO: ‘Online Grocery Sales May Lag’

By AJ Fabino

September 20, 12:28 PM

Adding to the cart, but not checking out yet — that's how Bernie McTernan at Needham & Company described the situation after Instacart (NASDAQ: CART) made a splash on the

AMZN

Fennec Pharmaceuticals Granted FDA Approval For PEDMARK

Related Posts

Morgan Stanley Maintains Overweight on Allegiant Travel, Lowers Price Target to $200

Couchbase Sees Q3 Revenue $42.7M-$43.3M Vs $43.63M Est.; FY24 Revenue $171.7M-$174.7M Vs $173.39M Est.

Cognex Clocks 29% Revenue Decline In Q1, Mirroring Broader Macroeconomic Softness

Why This Instacart Analyst Is Sidelined After IPO: ‘Online Grocery Sales May Lag’